Vascular Disease Management Increasingly Important
Current issue of Progress in Cardiovascular Diseases Explores Recent Evidence-Based Vascular Medicine
Philadelphia, PA, July 19, 2011 – As the population ages and obesity and diabetes increase, more people suffer from noncardiac vascular diseases. In the July/August issue of Progress in Cardiovascular Diseases, published by Elsevier, a series of articles from recognized experts on key topics in vascular disease and endovascular medicine provide an insightful compendium of the evidence available to help improve the care of this complex patient population.
“Over the past decade, interest in the management of patients with noncardiac vascular disease has exploded,” commented guest editors Christopher J. White, MD, The John Ochsner Heart & Vascular Institute, Ochsner Clinical Foundation, New Orleans, LA, and Michael R. Jaff, DO, Massachusetts General Hospital Vascular Center, Boston, MA. “There are several potential explanations for this, including the aging population, the increasing prevalence of diabetes mellitus and obesity, rapidly evolving endovascular technologies, and increasing interest among vascular specialists to perform cutting-edge, minimally invasive procedures. Despite this interest, the literature remains devoid of many high-level scientific studies aiding the clinician in the practice of evidence-based vascular medicine. This issue of Progress in Cardiovascular Diseases was developed to provide an up-to-date summary of the most recent evidence by expert clinicians in vascular and endovascular medicine.”
“This timely symposium offers the clinical cardiologist much needed access to the latest developments and capacities in an arena that is expanding rapidly and will continue to do so,” stated Editor-in-Chief Henry Greenberg, MD, Columbia University College of Physicians and Surgeons and St. Luke's Roosevelt Hospital, New York, NY.
Comprehensive Medical Management of Peripheral Artery Disease
Sanjay Gandhi, Ido Weinberg, Ronan Margey, and Michael R. Jaff
Peripheral arterial disease is the most underrecognized and undertreated atherosclerotic syndrome in the general population. Patients with PAD are at very high risk for future cardiovascular events and mortality. Once the diagnosis of PAD is established, all patients must receive comprehensive intervention, including aggressive atherosclerotic risk factor modification—namely tobacco cessation, weight loss, antiplatelet therapy, lipid-lowering therapy, control of diabetes mellitus, and high blood pressure.
Carotid Stenting or Carotid Surgery in Average Surgical-Risk Patients: Interpreting the Conflicting Clinical Trial Data
William A. Gray
The author describes the previous clinical data comparing carotid artery stenting (CAS), carotid angioplasty (CA) and carotid endarterectomy (CEA) and cautions that many studies have methodologic concerns. He concludes that the available evidence supports CAS as an equivalent, effective treatment for carotid artery disease.
Treatment Strategies for Carotid Stenosis in Patients at Increased Risk for Surgery
Robert D. Safian
Symptomatic patients with severe carotid stenosis (CS) who are at high risk for CEA should be considered for CAS. In asymptomatic patients with CS 80% or greater but who are at high risk for CEA should undergo careful risk benefit assessment. Patients who have normal cognitive function, favorable aortic arch and carotid artery anatomy, and a likelihood of survival 3 years or greater should be considered for CAS, whereas patients with multiple unfavorable features may be treated with optimal medical therapy, without surgical intervention.
Renal Artery Stenosis: Optimizing Diagnosis and Treatment
William R. Colyer, Ehab Eltahawy, and Christopher J. Cooper
Renal artery stenosis (RAS) is a common problem that affects young patients with fibromuscular dysplasia and old patients with atherosclerosis. Treatment of FMD with balloon angioplasty and antihypertensive medications is well accepted. Treatment of atherosclerotic RAS remains controversial, largely because of the disparity in results between observational studies suggesting a treatment advantage and randomized trials that have failed to detect such differences in treatment outcome.
Chronic Mesenteric Ischemia: Diagnosis and Management
Christopher J. White
Although chronic mesenteric ischemia (CMI) is the most common vascular disorder of the intestines, it occurs infrequently. Since randomized control trials are difficult to perform, case series can be used to evaluate treatment outcomes. The current treatment recommendation is that patients who are candidates for either surgery or percutaneous therapy should initially receive percutaneous therapy with stent placement.
Claudication: Treatment Options for Femoropopliteal Disease
Martin Schillinger and Erich Minar
Walking limitation due to arterial obstruction to the legs can be disabling, especially in older patients. This article outlines the recommended treatments depending on the patients' symptoms and their reduction in quality of life.
Critical Limb Ischemia: Endovascular Strategies for Limb Salvage
Philip B. Dattiloa and Ivan P. Casserly
As the most severe manifestation of peripheral artery disease (PAD), critical limb ischemia (CLI) can result in the loss of a limb. The authors discuss how an endovascular-first approach to treatment of CLI can lead to positive outcomes. In addition, they note that optimizing overall clinical care after revascularization may hold the key to altering the poor long-term prognosis of patients with CLI.
Venous Ablation Therapy: Indications and Outcomes
Venous disease is a progressive, debilitating, and recurrent problem, which until recently was often undertreated. During the past decade, an explosion in the treatment options has occurred. Endovenous ablation therapy has nearly replaced the conventional surgical treatments for patients with superficial venous insufficiency. These newer techniques are much less invasive and consequently have reduced risks of wound complications or bleeding. With the lower procedural risks and the dramatically shortened recovery times, earlier intervention can be done.
Endovascular Therapies to Treat Iliofemoral Deep Venous Thrombosis
J. Stephen Jenkins
Although venous thromboembolism (VTE) is responsible for more than 250,000 hospital admissions per year in the United States, published guidelines do not adequately address invasive therapies for iliofemoral deep venous thrombosis (DVT). Ileofemoral DVT generally has a worse prognosis than other forms of lower-limb DVT. The authors review the anticoagulation management and catheter-based invasive therapies for the treatment of this condition.
These articles appear in Progress in Cardiovascular Diseases, Volume 54, Number 1, (July/August 2011): Updates in Vascular Medicine and Endovascular Intervention, Guest Editors Christopher J. White, MD, and Michael R. Jaff, DO, published by Elsevier.
# # #
Notes for Editors
Full text of the articles is available to credentialed journalists upon request. To obtain copies contact Francesca Costanzo at 215-239-3249, firstname.lastname@example.org.
Journalists wishing to set up interviews should contact Henry Greenberg, MD, Editor-in-Chief, Progress in Cardiovascular Diseases, Associate Professor of Clinical Medicine & Faculty, Institute of Human Nutrition, Columbia University College of Physicians and Surgeons, Associate Director, Cardiology, St. Luke's Roosevelt Hospital, New York, NY 10019, +1 212-523-7370,email@example.com.
About the Editor-in-Chief
Dr. Greenberg is an Associate Professor of Clinical Medicine at Columbia University’s College of Physicians and Surgeons and a cardiologist at St. Luke’s Roosevelt Hospital in New York City. He has recently joined the Epidemiology faculty at Mailman School of Public Health, also at Columbia University, where he will teach a course of the prevention of CVD in the developing world.
Christopher J. White, MD, FSCAI, FACC, FAHA, FESC
Professor of Medicine, Department of Cardiovascular Diseases
The John Ochsner Heart & Vascular Institute
Ochsner Clinical Foundation, New Orleans, LA
Michael R. Jaff, DO, FACP, FACC, FAHA
Massachusetts General Hospital Vascular Center, Boston, MA
About Progress in Cardiovascular Diseases
Each issue of Progress in Cardiovascular Diseases ( www.onlinepcd.com) comprehensively covers a single topic in the understanding and treatment of disorders of the heart and circulation. Some issues include special articles, definitive reviews that capture the state of the art in the management of particular clinical problems in cardiology.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.